#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0028] There are many advantages of the present invention.
1-1	0-1	[	_	_	
1-2	1-5	0028	_	_	
1-3	5-6	]	_	_	
1-4	7-12	There	_	_	
1-5	13-16	are	_	_	
1-6	17-21	many	_	_	
1-7	22-32	advantages	_	_	
1-8	33-35	of	_	_	
1-9	36-39	the	_	_	
1-10	40-47	present	_	_	
1-11	48-57	invention	_	_	
1-12	57-58	.	_	_	

#Text=For instance, unlike the hybridization in immobilization-based DNA detections which occur on a solution-electrode interface as afore-discussed, the hybridization in the immobilization-free scheme of the instant invention occurs in a homogeneous solution phase and greatly reduces the assay time with a higher hybridization efficiency.
2-1	59-62	For	_	_	
2-2	63-71	instance	_	_	
2-3	71-72	,	_	_	
2-4	73-79	unlike	_	_	
2-5	80-83	the	_	_	
2-6	84-97	hybridization	_	_	
2-7	98-100	in	_	_	
2-8	101-121	immobilization-based	_	_	
2-9	122-125	DNA	_	_	
2-10	126-136	detections	_	_	
2-11	137-142	which	_	_	
2-12	143-148	occur	_	_	
2-13	149-151	on	_	_	
2-14	152-153	a	_	_	
2-15	154-172	solution-electrode	_	_	
2-16	173-182	interface	_	_	
2-17	183-185	as	_	_	
2-18	186-201	afore-discussed	_	_	
2-19	201-202	,	_	_	
2-20	203-206	the	_	_	
2-21	207-220	hybridization	_	_	
2-22	221-223	in	_	_	
2-23	224-227	the	_	_	
2-24	228-247	immobilization-free	_	_	
2-25	248-254	scheme	_	_	
2-26	255-257	of	_	_	
2-27	258-261	the	_	_	
2-28	262-269	instant	_	_	
2-29	270-279	invention	_	_	
2-30	280-286	occurs	_	_	
2-31	287-289	in	_	_	
2-32	290-291	a	_	_	
2-33	292-303	homogeneous	_	_	
2-34	304-312	solution	_	_	
2-35	313-318	phase	_	_	
2-36	319-322	and	_	_	
2-37	323-330	greatly	_	_	
2-38	331-338	reduces	_	_	
2-39	339-342	the	_	_	
2-40	343-348	assay	_	_	
2-41	349-353	time	_	_	
2-42	354-358	with	_	_	
2-43	359-360	a	_	_	
2-44	361-367	higher	_	_	
2-45	368-381	hybridization	_	_	
2-46	382-392	efficiency	_	_	
2-47	392-393	.	_	_	

#Text=Thus, the signal-on immobilization-free electrochemical DNA detection of the instant invention can produce more reliable results than the afore-mentioned signal-off method and have a good potential to be developed into a simple and robust electrochemical DNA detection for point-of-care testing.
3-1	394-398	Thus	_	_	
3-2	398-399	,	_	_	
3-3	400-403	the	_	_	
3-4	404-413	signal-on	*[1]	7-3[2_1]|7-67[3_1]	
3-5	414-433	immobilization-free	*[1]	_	
3-6	434-449	electrochemical	*[1]	_	
3-7	450-453	DNA	*[1]	_	
3-8	454-463	detection	*[1]	_	
3-9	464-466	of	_	_	
3-10	467-470	the	_	_	
3-11	471-478	instant	_	_	
3-12	479-488	invention	_	_	
3-13	489-492	can	_	_	
3-14	493-500	produce	_	_	
3-15	501-505	more	_	_	
3-16	506-514	reliable	_	_	
3-17	515-522	results	_	_	
3-18	523-527	than	_	_	
3-19	528-531	the	_	_	
3-20	532-547	afore-mentioned	_	_	
3-21	548-558	signal-off	_	_	
3-22	559-565	method	_	_	
3-23	566-569	and	_	_	
3-24	570-574	have	_	_	
3-25	575-576	a	_	_	
3-26	577-581	good	_	_	
3-27	582-591	potential	_	_	
3-28	592-594	to	_	_	
3-29	595-597	be	_	_	
3-30	598-607	developed	_	_	
3-31	608-612	into	_	_	
3-32	613-614	a	_	_	
3-33	615-621	simple	_	_	
3-34	622-625	and	_	_	
3-35	626-632	robust	_	_	
3-36	633-648	electrochemical	_	_	
3-37	649-652	DNA	_	_	
3-38	653-662	detection	_	_	
3-39	663-666	for	_	_	
3-40	667-680	point-of-care	_	_	
3-41	681-688	testing	_	_	
3-42	688-689	.	_	_	

#Text=For example, it may be integrated into hand-held instruments for point-of-care DNA analysis.
4-1	690-693	For	_	_	
4-2	694-701	example	_	_	
4-3	701-702	,	_	_	
4-4	703-705	it	_	_	
4-5	706-709	may	_	_	
4-6	710-712	be	_	_	
4-7	713-723	integrated	_	_	
4-8	724-728	into	_	_	
4-9	729-738	hand-held	_	_	
4-10	739-750	instruments	_	_	
4-11	751-754	for	_	_	
4-12	755-768	point-of-care	_	_	
4-13	769-772	DNA	_	_	
4-14	773-781	analysis	_	_	
4-15	781-782	.	_	_	

#Text=This provides a significant contribution to the medical diagnostics industry as well as to environmental monitoring for decentralized applications.
#Text=[0029] Further, the solution method of the instant invention operates in a "signal-on" mode in which the presence of target DNA results in the increment of the signal.
5-1	783-787	This	_	_	
5-2	788-796	provides	_	_	
5-3	797-798	a	_	_	
5-4	799-810	significant	_	_	
5-5	811-823	contribution	_	_	
5-6	824-826	to	_	_	
5-7	827-830	the	_	_	
5-8	831-838	medical	_	_	
5-9	839-850	diagnostics	_	_	
5-10	851-859	industry	_	_	
5-11	860-862	as	_	_	
5-12	863-867	well	_	_	
5-13	868-870	as	_	_	
5-14	871-873	to	_	_	
5-15	874-887	environmental	_	_	
5-16	888-898	monitoring	_	_	
5-17	899-902	for	_	_	
5-18	903-916	decentralized	_	_	
5-19	917-929	applications	_	_	
5-20	929-930	.	_	_	
5-21	931-932	[	_	_	
5-22	932-936	0029	_	_	
5-23	936-937	]	_	_	
5-24	938-945	Further	_	_	
5-25	945-946	,	_	_	
5-26	947-950	the	_	_	
5-27	951-959	solution	_	_	
5-28	960-966	method	_	_	
5-29	967-969	of	_	_	
5-30	970-973	the	_	_	
5-31	974-981	instant	_	_	
5-32	982-991	invention	_	_	
5-33	992-1000	operates	_	_	
5-34	1001-1003	in	_	_	
5-35	1004-1005	a	_	_	
5-36	1006-1007	"	_	_	
5-37	1007-1016	signal-on	_	_	
5-38	1016-1017	"	_	_	
5-39	1018-1022	mode	_	_	
5-40	1023-1025	in	_	_	
5-41	1026-1031	which	_	_	
5-42	1032-1035	the	_	_	
5-43	1036-1044	presence	_	_	
5-44	1045-1047	of	_	_	
5-45	1048-1054	target	_	_	
5-46	1055-1058	DNA	_	_	
5-47	1059-1066	results	_	_	
5-48	1067-1069	in	_	_	
5-49	1070-1073	the	_	_	
5-50	1074-1083	increment	_	_	
5-51	1084-1086	of	_	_	
5-52	1087-1090	the	_	_	
5-53	1091-1097	signal	_	_	
5-54	1097-1098	.	_	_	

#Text=Therefore, it is unlikely that any factor other than the presence of target DNA would lead to the appearance or enhancement of the specific electrochemical signal.
#Text=[0030] For the detection and/or quantification of nucleic acid amplification product is performed in real time during the PCR reaction, it is important to note that the method and system according to this invention are thermally stable, having a negligible inhibitory effect on the PCR reaction.
6-1	1099-1108	Therefore	_	_	
6-2	1108-1109	,	_	_	
6-3	1110-1112	it	_	_	
6-4	1113-1115	is	_	_	
6-5	1116-1124	unlikely	_	_	
6-6	1125-1129	that	_	_	
6-7	1130-1133	any	_	_	
6-8	1134-1140	factor	_	_	
6-9	1141-1146	other	_	_	
6-10	1147-1151	than	_	_	
6-11	1152-1155	the	_	_	
6-12	1156-1164	presence	_	_	
6-13	1165-1167	of	_	_	
6-14	1168-1174	target	_	_	
6-15	1175-1178	DNA	_	_	
6-16	1179-1184	would	_	_	
6-17	1185-1189	lead	_	_	
6-18	1190-1192	to	_	_	
6-19	1193-1196	the	_	_	
6-20	1197-1207	appearance	_	_	
6-21	1208-1210	or	_	_	
6-22	1211-1222	enhancement	_	_	
6-23	1223-1225	of	_	_	
6-24	1226-1229	the	_	_	
6-25	1230-1238	specific	_	_	
6-26	1239-1254	electrochemical	_	_	
6-27	1255-1261	signal	_	_	
6-28	1261-1262	.	_	_	
6-29	1263-1264	[	_	_	
6-30	1264-1268	0030	_	_	
6-31	1268-1269	]	_	_	
6-32	1270-1273	For	_	_	
6-33	1274-1277	the	_	_	
6-34	1278-1287	detection	_	_	
6-35	1288-1291	and	_	_	
6-36	1291-1292	/	_	_	
6-37	1292-1294	or	_	_	
6-38	1295-1309	quantification	_	_	
6-39	1310-1312	of	_	_	
6-40	1313-1320	nucleic	_	_	
6-41	1321-1325	acid	_	_	
6-42	1326-1339	amplification	_	_	
6-43	1340-1347	product	_	_	
6-44	1348-1350	is	_	_	
6-45	1351-1360	performed	_	_	
6-46	1361-1363	in	_	_	
6-47	1364-1368	real	_	_	
6-48	1369-1373	time	_	_	
6-49	1374-1380	during	_	_	
6-50	1381-1384	the	_	_	
6-51	1385-1388	PCR	_	_	
6-52	1389-1397	reaction	_	_	
6-53	1397-1398	,	_	_	
6-54	1399-1401	it	_	_	
6-55	1402-1404	is	_	_	
6-56	1405-1414	important	_	_	
6-57	1415-1417	to	_	_	
6-58	1418-1422	note	_	_	
6-59	1423-1427	that	_	_	
6-60	1428-1431	the	_	_	
6-61	1432-1438	method	_	_	
6-62	1439-1442	and	_	_	
6-63	1443-1449	system	_	_	
6-64	1450-1459	according	_	_	
6-65	1460-1462	to	_	_	
6-66	1463-1467	this	_	_	
6-67	1468-1477	invention	_	_	
6-68	1478-1481	are	_	_	
6-69	1482-1491	thermally	_	_	
6-70	1492-1498	stable	_	_	
6-71	1498-1499	,	_	_	
6-72	1500-1506	having	_	_	
6-73	1507-1508	a	_	_	
6-74	1509-1519	negligible	_	_	
6-75	1520-1530	inhibitory	_	_	
6-76	1531-1537	effect	_	_	
6-77	1538-1540	on	_	_	
6-78	1541-1544	the	_	_	
6-79	1545-1548	PCR	_	_	
6-80	1549-1557	reaction	_	_	
6-81	1557-1558	.	_	_	

#Text=Also, this method is accurate, reproducible, and safe, even in the absence of an additional step of washing off of unreacted molecules, especially the soluble and non-incorporated labeled molecules and markers employed in the reaction.
#Text=[0031] When compared to optically-based devices, the present invention provides a technology that results in significantly reduced expenses; more particularly, this method may be employed in miniaturized devices, e.g. a portable real time PCR analyzer, which is currently unavailable in the market place.
#Text=[0032] FIG. 1 shows a scheme of a solid-phase method employing a red-ox probe according to one embodiment of the present invention.
7-1	1559-1563	Also	_	_	
7-2	1563-1564	,	_	_	
7-3	1565-1569	this	*[2]	_	
7-4	1570-1576	method	*[2]	_	
7-5	1577-1579	is	_	_	
7-6	1580-1588	accurate	_	_	
7-7	1588-1589	,	_	_	
7-8	1590-1602	reproducible	_	_	
7-9	1602-1603	,	_	_	
7-10	1604-1607	and	_	_	
7-11	1608-1612	safe	_	_	
7-12	1612-1613	,	_	_	
7-13	1614-1618	even	_	_	
7-14	1619-1621	in	_	_	
7-15	1622-1625	the	_	_	
7-16	1626-1633	absence	_	_	
7-17	1634-1636	of	_	_	
7-18	1637-1639	an	_	_	
7-19	1640-1650	additional	_	_	
7-20	1651-1655	step	_	_	
7-21	1656-1658	of	_	_	
7-22	1659-1666	washing	_	_	
7-23	1667-1670	off	_	_	
7-24	1671-1673	of	_	_	
7-25	1674-1683	unreacted	_	_	
7-26	1684-1693	molecules	_	_	
7-27	1693-1694	,	_	_	
7-28	1695-1705	especially	_	_	
7-29	1706-1709	the	_	_	
7-30	1710-1717	soluble	_	_	
7-31	1718-1721	and	_	_	
7-32	1722-1738	non-incorporated	_	_	
7-33	1739-1746	labeled	_	_	
7-34	1747-1756	molecules	_	_	
7-35	1757-1760	and	_	_	
7-36	1761-1768	markers	_	_	
7-37	1769-1777	employed	_	_	
7-38	1778-1780	in	_	_	
7-39	1781-1784	the	_	_	
7-40	1785-1793	reaction	_	_	
7-41	1793-1794	.	_	_	
7-42	1795-1796	[	_	_	
7-43	1796-1800	0031	_	_	
7-44	1800-1801	]	_	_	
7-45	1802-1806	When	_	_	
7-46	1807-1815	compared	_	_	
7-47	1816-1818	to	_	_	
7-48	1819-1834	optically-based	_	_	
7-49	1835-1842	devices	_	_	
7-50	1842-1843	,	_	_	
7-51	1844-1847	the	_	_	
7-52	1848-1855	present	_	_	
7-53	1856-1865	invention	_	_	
7-54	1866-1874	provides	_	_	
7-55	1875-1876	a	_	_	
7-56	1877-1887	technology	_	_	
7-57	1888-1892	that	_	_	
7-58	1893-1900	results	_	_	
7-59	1901-1903	in	_	_	
7-60	1904-1917	significantly	_	_	
7-61	1918-1925	reduced	_	_	
7-62	1926-1934	expenses	_	_	
7-63	1934-1935	;	_	_	
7-64	1936-1940	more	_	_	
7-65	1941-1953	particularly	_	_	
7-66	1953-1954	,	_	_	
7-67	1955-1959	this	*[3]	_	
7-68	1960-1966	method	*[3]	_	
7-69	1967-1970	may	_	_	
7-70	1971-1973	be	_	_	
7-71	1974-1982	employed	_	_	
7-72	1983-1985	in	_	_	
7-73	1986-1998	miniaturized	_	_	
7-74	1999-2006	devices	_	_	
7-75	2006-2007	,	_	_	
7-76	2008-2011	e.g	_	_	
7-77	2011-2012	.	_	_	
7-78	2013-2014	a	_	_	
7-79	2015-2023	portable	_	_	
7-80	2024-2028	real	_	_	
7-81	2029-2033	time	_	_	
7-82	2034-2037	PCR	_	_	
7-83	2038-2046	analyzer	_	_	
7-84	2046-2047	,	_	_	
7-85	2048-2053	which	_	_	
7-86	2054-2056	is	_	_	
7-87	2057-2066	currently	_	_	
7-88	2067-2078	unavailable	_	_	
7-89	2079-2081	in	_	_	
7-90	2082-2085	the	_	_	
7-91	2086-2092	market	_	_	
7-92	2093-2098	place	_	_	
7-93	2098-2099	.	_	_	
7-94	2100-2101	[	_	_	
7-95	2101-2105	0032	_	_	
7-96	2105-2106	]	_	_	
7-97	2107-2110	FIG	_	_	
7-98	2110-2111	.	_	_	
7-99	2112-2113	1	_	_	
7-100	2114-2119	shows	_	_	
7-101	2120-2121	a	_	_	
7-102	2122-2128	scheme	_	_	
7-103	2129-2131	of	_	_	
7-104	2132-2133	a	_	_	
7-105	2134-2145	solid-phase	_	_	
7-106	2146-2152	method	_	_	
7-107	2153-2162	employing	_	_	
7-108	2163-2164	a	_	_	
7-109	2165-2171	red-ox	_	_	
7-110	2172-2177	probe	_	_	
7-111	2178-2187	according	_	_	
7-112	2188-2190	to	_	_	
7-113	2191-2194	one	_	_	
7-114	2195-2205	embodiment	_	_	
7-115	2206-2208	of	_	_	
7-116	2209-2212	the	_	_	
7-117	2213-2220	present	_	_	
7-118	2221-2230	invention	_	_	
7-119	2230-2231	.	_	_	
